These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

616 related articles for article (PubMed ID: 25269710)

  • 1. Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type.
    Johnson C; Connors GR; Oaks J; Han S; Truong A; Richardson B; Lechtzin N; Mammen AL; Casciola-Rosen L; Christopher-Stine L; Danoff SK
    Respir Med; 2014 Oct; 108(10):1542-8. PubMed ID: 25269710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response.
    Bauhammer J; Blank N; Max R; Lorenz HM; Wagner U; Krause D; Fiehn C
    J Rheumatol; 2016 Aug; 43(8):1566-74. PubMed ID: 27252419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Profiles and Prognosis of Patients with Distinct Antisynthetase Autoantibodies.
    Shi J; Li S; Yang H; Zhang Y; Peng Q; Lu X; Wang G
    J Rheumatol; 2017 Jul; 44(7):1051-1057. PubMed ID: 28461650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group.
    Trallero-Araguás E; Grau-Junyent JM; Labirua-Iturburu A; García-Hernández FJ; Monteagudo-Jiménez M; Fraile-Rodriguez G; Les-Bujanda I; Rodriguez-Carballeira M; Sáez-Comet L; Selva-O'Callaghan A;
    Semin Arthritis Rheum; 2016 Oct; 46(2):225-231. PubMed ID: 27139168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
    Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Ikezoe K; Sokai A; Nakatsuka Y; Taguchi Y; Hatta K; Noma S; Kobashi Y; Yoshizawa A; Oga T; Hirai T; Chin K; Nagai S; Izumi T; Mimori T; Mishima M
    Respir Med; 2017 Jun; 127():57-64. PubMed ID: 28461123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China.
    Zhan X; Yan W; Wang Y; Li Q; Shi X; Gao Y; Ye Q
    BMC Pulm Med; 2021 Feb; 21(1):57. PubMed ID: 33579248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease.
    Cavagna L; Caporali R; Abdì-Alì L; Dore R; Meloni F; Montecucco C
    J Rheumatol; 2013 Apr; 40(4):484-92. PubMed ID: 23418387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
    Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
    Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interstitial lung disease and myositis-specific and associated autoantibodies: Clinical manifestations, survival and the performance of the new ATS/ERS criteria for interstitial pneumonia with autoimmune features (IPAF).
    Mejía M; Herrera-Bringas D; Pérez-Román DI; Rivero H; Mateos-Toledo H; Castorena-García P; Figueroa JE; Rojas-Serrano J
    Respir Med; 2017 Feb; 123():79-86. PubMed ID: 28137500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome.
    Lega JC; Fabien N; Reynaud Q; Durieu I; Durupt S; Dutertre M; Cordier JF; Cottin V
    Autoimmun Rev; 2014 Sep; 13(9):883-91. PubMed ID: 24704867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD).
    Rojas-Serrano J; Herrera-Bringas D; Mejía M; Rivero H; Mateos-Toledo H; Figueroa JE
    Clin Rheumatol; 2015 Sep; 34(9):1563-9. PubMed ID: 26219488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisynthetase syndrome with anti-Jo1 antibodies in 48 patients: pulmonary involvement predicts disease-modifying antirheumatic drug use.
    Stanciu R; Guiguet M; Musset L; Touitou D; Beigelman C; Rigolet A; Costedoat-Chalumeau N; Allenbach Y; Hervier B; Dubourg O; Maisonobe T; Charuel JL; Behin A; Herson S; Amoura Z; Grenier P; Benveniste O
    J Rheumatol; 2012 Sep; 39(9):1835-9. PubMed ID: 22859355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary Involvement in the Antisynthetase Syndrome: A Comparative Cross-sectional Study.
    Andersson H; Aaløkken TM; Günther A; Mynarek GK; Garen T; Lund MB; Molberg Ø
    J Rheumatol; 2016 Jun; 43(6):1107-13. PubMed ID: 27036381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The shades of anti-Jo1 positive antisynthetase syndrome in a Hungarian cohort].
    Szabó K; Nagy-Vincze M; Bodoki L; Hodosi K; Dankó K; Griger Z
    Orv Hetil; 2016 Apr; 157(15):575-83. PubMed ID: 27039996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody.
    Marie I; Hatron PY; Dominique S; Cherin P; Mouthon L; Menard JF; Levesque H; Jouen F
    Semin Arthritis Rheum; 2012 Jun; 41(6):890-9. PubMed ID: 22078416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome.
    Zamora AC; Hoskote SS; Abascal-Bolado B; White D; Cox CW; Ryu JH; Moua T
    Respir Med; 2016 Sep; 118():39-45. PubMed ID: 27578469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characterisation of a multicentre nationwide cohort of patients with antisynthetase syndrome.
    Martins P; Dourado E; Melo AT; Samões B; Sousa M; Freitas R; Lourenço MH; Fernandes B; Costa E; Parente H; Martins F; Fonseca JE; Cordeiro I; Romão VC; Khmelinskii N; Campanilho-Marques R
    ARP Rheumatol; 2022 Nov; 1(ARP Rheumatology, nº3 2022):190-196. PubMed ID: 35891592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical value of myositis antibodies in patients with connective tissue disease-associated interstitial lung diseases].
    Xie MM; Zou RY; Li Y; Liu Y; Chen LL; Liu XQ; Zhao Q; Ding JJ; Chen ZY; Cai HR
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Oct; 42(10):765-770. PubMed ID: 31594111
    [No Abstract]   [Full Text] [Related]  

  • 19. Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls.
    Labirua A; Lundberg IE
    Curr Opin Rheumatol; 2010 Nov; 22(6):633-8. PubMed ID: 20827201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interstitial lung disease outcomes by high-resolution computed tomography (HRCT) in Anti-Jo1 antibody-positive polymyositis patients: a single centre study and review of the literature.
    Ingegnoli F; Lubatti C; Ingegnoli A; Boracchi P; Zeni S; Meroni PL
    Autoimmun Rev; 2012 Mar; 11(5):335-40. PubMed ID: 21985773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.